Panel backs Celgene's blood-disorder drug

09/15/2005 | Wall Street Journal, The

The panel of experts voted 10-5 to back the Celgene drug Revlimid for patients with myelodysplastic syndromes, based on Phase II studies of patients with MDS who have a certain genetic abnormality. The majority of those voting against approval said they wanted to wait for data from a Phase III study now beginning to enroll patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care